| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1029697306 |
| P356 | DOI | 10.1007/S40291-016-0232-1 |
| P3181 | OpenCitations bibliographic resource ID | 3639943 |
| P932 | PMC publication ID | 5107185 |
| P698 | PubMed publication ID | 27604084 |
| P2093 | author name string | Adriaan A. van Bodegraven | |
| Geerten P. van Nieuw Amerongen | |||
| Margien L. Seinen | |||
| Nanne K. H. de Boer | |||
| P2860 | cites work | Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review | Q22250934 |
| Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis | Q24200757 | ||
| Evidence for a functional genetic polymorphism of the Rho-GTPase Rac1. Implication in azathioprine response? | Q42747549 | ||
| Single nucleotide polymorphisms that increase expression of the guanosine triphosphatase RAC1 are associated with ulcerative colitis | Q42859669 | ||
| 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. | Q43928996 | ||
| Differential Control of Cell Cycle, Proliferation, and Survival of Primary T Lymphocytes by Purine and Pyrimidine Nucleotides | Q44432122 | ||
| 6-Mercaptopurine reduces macrophage activation and gut epithelium proliferation through inhibition of GTPase Rac1. | Q44698407 | ||
| Thiopurine effectiveness in patients with Crohn's disease: a study of genetic and clinical predictive factors | Q45344005 | ||
| Differential role of Rho GTPases in intestinal epithelial barrier regulation in vitro | Q45753289 | ||
| Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. | Q45930884 | ||
| American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease | Q46229958 | ||
| Novel intermediate of Rac GTPase activation by guanine nucleotide exchange factor | Q46454806 | ||
| Confirmation of association of IRGM and NCF4 with ileal Crohn's disease in a population-based cohort | Q46518390 | ||
| A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease | Q46724666 | ||
| 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease | Q46761199 | ||
| Driving Rho GTPase activity in endothelial cells regulates barrier integrity. | Q50276491 | ||
| Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease. | Q50561961 | ||
| Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. | Q50649054 | ||
| Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease. | Q51611690 | ||
| Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. | Q53648891 | ||
| Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases. | Q53959942 | ||
| Suppression of p21Rac signaling and increased innate immunity mediate remission in Crohn's disease. | Q54357723 | ||
| Infliximab, azathioprine, or combination therapy for Crohn's disease | Q56988763 | ||
| Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients | Q59509451 | ||
| [Guideline 'Diagnosis and treatment of inflammatory bowel disease in adults'. I. Diagnosis and treatment] | Q82206319 | ||
| Gp91(phox) contributes to the development of experimental inflammatory bowel disease | Q83412162 | ||
| Rac1 Polymorphisms and Thiopurine Efficacy in Children With Inflammatory Bowel Disease | Q87137704 | ||
| Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis | Q87263251 | ||
| GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo | Q24685451 | ||
| Structural Mechanisms and Drug Discovery Prospects of Rho GTPases | Q26745863 | ||
| Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease | Q26853181 | ||
| Role of Rho kinase signal pathway in inflammatory bowel disease | Q27006502 | ||
| Rac activation by the T-cell receptor inhibits T cell migration | Q27320959 | ||
| Rho GTPases in cell biology | Q27860969 | ||
| The guanine nucleotide-binding switch in three dimensions | Q28131710 | ||
| Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease | Q28143558 | ||
| NADPH oxidase complex and IBD candidate gene studies: identification of a rare variant in NCF2 that results in reduced binding to RAC2 | Q28247419 | ||
| GDIs: central regulatory molecules in Rho GTPase activation | Q28253312 | ||
| GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors | Q29547630 | ||
| Inflammatory bowel disease | Q29616286 | ||
| Genetics and pathogenesis of inflammatory bowel disease | Q29616350 | ||
| Guanine nucleotide exchange factors for Rho GTPases: turning on the switch | Q29618403 | ||
| Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease | Q33895677 | ||
| Azathioprine for maintaining remission of Crohn's disease | Q33908475 | ||
| Rac2-deficiency leads to exacerbated and protracted colitis in response to Citrobacter rodentium infection | Q34684714 | ||
| Rac signaling in breast cancer: a tale of GEFs and GAPs. | Q35854151 | ||
| T cell apoptosis and inflammatory bowel disease | Q35915896 | ||
| Regulation of innate immunity by Rho GTPases | Q36064211 | ||
| The role of the alpha4 integrin-paxillin interaction in regulating leukocyte trafficking | Q36526745 | ||
| Regulation of the phagocyte NADPH oxidase by Rac GTPase | Q36598790 | ||
| Current knowledge of the large RhoGAP family of proteins | Q36707513 | ||
| Chimaerins: GAPs that bridge diacylglycerol signalling and the small G-protein Rac. | Q36754796 | ||
| Rho family GTPases and their regulators in lymphocytes. | Q36982689 | ||
| Thiopurine Prodrugs Mediate Immunosuppressive Effects by Interfering with Rac1 Protein Function | Q37034422 | ||
| On therapeutic drug monitoring of thiopurines in inflammatory bowel disease; pharmacology, pharmacogenomics, drug intolerance and clinical relevance | Q37705504 | ||
| The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management | Q37814541 | ||
| Regulation of small GTPases at epithelial cell-cell junctions | Q37903873 | ||
| Small Rho GTPases in the control of cell shape and mobility | Q38166254 | ||
| Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms | Q38839225 | ||
| Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease | Q39020345 | ||
| CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes | Q39744964 | ||
| Rac1 mediates intestinal epithelial cell apoptosis via JNK. | Q40263028 | ||
| Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins | Q42052555 | ||
| Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammation. | Q42609911 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | enzyme | Q8047 |
| peptide | Q172847 | ||
| heterocyclic compound | Q193430 | ||
| inflammatory bowel diseases | Q917447 | ||
| transport protein | Q2111029 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 551-557 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Molecular Diagnosis and Therapy | Q15758832 |
| P1476 | title | Rac Attack: Modulation of the Small GTPase Rac in Inflammatory Bowel Disease and Thiopurine Therapy | |
| P478 | volume | 20 |
| Q48004039 | A functional genomics predictive network model identifies regulators of inflammatory bowel disease |
| Q47426181 | Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease |
| Q64269853 | Curcumin and resveratrol suppress dextran sulfate sodium‑induced colitis in mice |
| Q48507180 | Inhibition of Rac family protein impairs colitis and colitis-associated cancer in mice. |
| Q41198135 | Pharmacology of Thiopurine Therapy in Inflammatory Bowel Disease and Complete Blood Cell Count Outcomes: A 5-Year Database Study |
| Q42697416 | Structures of a DNA Polymerase Inserting Therapeutic Nucleotide Analogues |
Search more.